Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy.
Chang, E
Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. [electronic resource] - Journal of immunotherapy (Hagerstown, Md. : 1997) - 88-90 p. digital
Publication Type: Comparative Study; Journal Article
1524-9557
10.1097/00002371-200101000-00010 doi
Adolescent
Adult
Aged
Antineoplastic Agents--administration & dosage
Child
Demography
Disease Susceptibility
Drug Resistance, Neoplasm
Female
Humans
Injections, Intravenous
Interleukin-2--administration & dosage
Male
Melanoma--drug therapy
Middle Aged
Skin Neoplasms--drug therapy
Treatment Outcome
Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. [electronic resource] - Journal of immunotherapy (Hagerstown, Md. : 1997) - 88-90 p. digital
Publication Type: Comparative Study; Journal Article
1524-9557
10.1097/00002371-200101000-00010 doi
Adolescent
Adult
Aged
Antineoplastic Agents--administration & dosage
Child
Demography
Disease Susceptibility
Drug Resistance, Neoplasm
Female
Humans
Injections, Intravenous
Interleukin-2--administration & dosage
Male
Melanoma--drug therapy
Middle Aged
Skin Neoplasms--drug therapy
Treatment Outcome